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ABSTRACT 
The mechanisms and temporal sequence underlying the association between major depressive 
disorder (MDD) and cardio-metabolic diseases are still poorly understood. Recent research 
suggests subtyping depression in order to study the mechanisms underlying its association with 
biological correlates. Accordingly, our aims were to 1) assess the prospective associations of the 
atypical, melancholic and unspecified subtypes of MDD with changes of fasting glucose, HDL-
cholesterol, triglycerides, systolic blood pressure and the incidence of the metabolic syndrome, 
2) determine the potential mediating role of inflammatory marker or adipokine concentrations, 
eating behaviors and changes in waist circumference during follow-up. Data stemmed from 
CoLaus|PsyCoLaus, a prospective cohort study including 35 to 66 year-old randomly selected 
residents of an urban area. Among the Caucasian participants who underwent the physical and 
psychiatric baseline evaluations, 2813 (87% participation rate) also accepted the physical follow-
up exam (mean follow-up duration=5.5 years). Symptoms of mental disorders were elicited using 
a semi-structured interview. The atypical MDD subtype, and only this subtype, was prospectively 
associated with a higher incidence of the metabolic syndrome (OR=2.49; 95% C.I. 1.30-4.77), a 
steeper increase of waist circumference (β=2.41; 95% C.I. 1.19-3.63) and independently of this, 
with a steeper increase of the fasting glucose level (β=131; 95% C.I. 38-225) during follow-up. 
These associations were not attributable to or mediated by inflammatory marker or adipokine 
concentrations, eating behaviors, comorbid psychiatric disorders or lifestyle factors. Accordingly, 
our results further support the subtyping of MDD and highlight the particular need for prevention 
and treatment of metabolic consequences in patients with atypical MDD.  
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INTRODUCTION 
Although the association between depressive disorders and cardiovascular diseases (CVD)1, 2 is 
well established, the mechanisms underlying this association are poorly understood3, 4. Besides 
lifestyle (smoking, reduced physical activity, unhealthy diet) and treatment factors (medication 
and non-adherence to treatment)3, 5, 6, increased vulnerability to cardio-metabolic diseases could 
be one explanation for the approximately doubled risk of CVD among depressed subjects1. 
Indeed, clinical and epidemiological studies revealed significant associations between 
depression and obesity7, diabetes8-10 and hypertension11. Two recent meta-analyses have also 
shown cross-sectional associations between depression and the metabolic syndrome, which 
encompasses obesity, diabetes, dyslipidemia and hypertension12,13. The results of the 11 
prospective cohort studies included in one of these two meta-analyses13 suggested a 
bidirectional association. However, the measured effect sizes varied largely across studies, 
which was most likely to be attributable to the heterogeneity of depression and large 
methodological variance across studies. Moreover, among the four studies that prospectively 
assessed the effect of depression on the incidence of the metabolic syndrome, only one14, which 
was restricted to 42 to 52 year-old women, relied on a direct diagnostic interview, whereas the 
others assessed depressive symptoms using rating scales. However, these scales do not 
generally allow for characterization into depression subtypes and do not take into account the 
frequent occurrence of comorbid mental disorders or past psychopathology.  
 
Given the heterogeneity of depression in terms of symptom manifestations, course and 
response to pharmacological treatment15, 16, subtyping depression is likely to be a more 
promising approach to elucidate the mechanisms underlying associations with cardio-metabolic 
risk factors than studying depression as a whole5. It has been hypothesized that depression 
subtypes are differently associated with biological mechanisms: the atypical subtype, mainly 
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characterized by increased appetite and hypersomnia, could be more strongly related to the 
metabolic syndrome and inflammation up-regulations and the melancholic subtype to 
dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis15, 17-19. Cross-sectional research 
has already provided support for associations between atypical depression and obesity 
markers20-22, diabetes21 or fasting glucose22, triglycerides22, 23 and the metabolic syndrome21, 22, 24, 
but prospective data which could provide clues to the direction of causality are still scarce. 
Following a community sample over more than 5 years, we could demonstrate a strong 
prospective association between Major Depressive Disorder (MDD) with atypical features and a 
steeper increase in body-mass index (BMI), waist circumference and fat-mass25. Similarly, a 
clinical cohort study conducted in the Netherlands has recently documented the persistence of a 
higher BMI, a higher prevalence and a larger number of components of the metabolic syndrome 
over six years in patients with atypical depression as compared to controls26. However, no study 
so far has prospectively assessed associations between depression subtypes and the specific 
components of the metabolic syndrome other than waist circumference. Therefore, it remains 
elusive whether the association between atypical MDD and the metabolic syndrome is explained 
by waist circumference increase alone or whether additional independent cardio-metabolic 
dysregulations are also involved. Likewise, it has not yet been tested to which degree cardio-
metabolic dysregulations related to atypical MDD are attributable to eating behaviors or the 
atypical depression symptom "increased appetite". Moreover, although several studies have 
documented associations between atypical depression and elevated inflammatory marker 
concentrations22, 27, 28, which may predispose to CVD and mortality3, 29, 30, no study has 
prospectively examined their function in the interplay between depression and cardio-metabolic 
dysregulations. Similarly, the role of leptin and adiponectin remains uncertain. The concentration 
of leptin, which is secreted by white adipose tissue and exerts a primary homeostatic function by 
suppressing nutritional intake and allowing energy expenditure31, has recently been found to be 
elevated in patients with atypical depression, most likely due to leptin resistance32.  
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Accordingly, using data from a population-based cohort, the aims of the present study were to 1) 
assess the prospective associations of the atypical, melancholic and unspecified subtypes of 
MDD with changes of the levels of fasting glucose, HDL-cholesterol, triglycerides, systolic blood 
pressure and the incidence of the metabolic syndrome, 2) determine the potential mediating role 
of baseline inflammatory marker (Hs-CRP, interleukin-1β, interleukin-6, tumor necrosis factor-α) 
or adipokine (leptin, adiponectin) concentrations, eating behaviors and changes of waist 
circumference during follow-up. Based on our cross-sectional findings we expected prospective 
associations between atypical depression, glucose level increase and the incidence of the 
metabolic syndrome. Regarding inflammation markers, adipokines and eating behaviors, we 
hypothesized that they could play a role as mediators in the associations between atypical 
depression and metabolic outcomes given that previous studies have shown them to be 
associated with both atypical depression22, 27, 28, 32 and metabolic outcomes20-22. In this case the 
associations between atypical depression and metabolic characteristics would decrease after 
introducing these variables into our models. 
 
SUBJECTS AND METHODS 
Participants	
The data of the present paper stemmed from CoLaus|PsyCoLaus33, 34, a prospective cohort 
study designed to study mental disorders and cardio-vascular risk factors in the community and 
to determine their associations. The sample was randomly selected from the residents of the city 
of Lausanne (Switzerland) from 2003 to 2006 according to the civil register. Sixty-seven percent 
of the 35 to 66 year-old participants of the physical baseline exam (n=5535) also accepted the 
psychiatric evaluation (Figure 1)34. Participants with a diagnosis of bipolar or schizoaffective 
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disorder, schizophrenia or eating disorder at baseline were excluded from the present analyses 
given that these disorders are likely to be associated with metabolic changes. Among the 
remaining 3560 subjects, 45 died during the follow-up (mean duration 5.5 years, s.d. 0.4 years) 
and 3056 accepted the physical follow-up evaluation (86.9% participation among survivors). 
Non-participants at follow-up were more likely than participants to be male, to have lower 
socioeconomic status, to live alone, to be less physically active, and to be current smokers. We 
needed to perform separate analyses on Caucasians (n=2813) and Non-Caucasians (n=243) 
because the baseline adipokine levels of the latter were not measured. 
 
Assessments	
Physical measures were taken in identical ways at the baseline and the follow-up visits. Detailed 
procedures are described elsewhere33. Waist circumference was measured over the unclothed 
abdomen at the narrowest point between the lowest rib and the iliac crest. Blood pressure was 
measured three times on the left arm after at least a 10-minute rest in the seated position. The 
mean of the last two measures was used. Venous blood samples were drawn after an overnight 
fast in order to measure the levels of glucose, HDL-cholesterol, LDL-cholesterol, triglycerides 
and insulin. Insulin resistance was estimated from measures of the glucose and insulin 
concentrations using the Homeostasis model assessment insulin resistance (HOMA-IR) index35. 
The metabolic syndrome was diagnosed according to the adjusted Adult Treatment Panel III 
criteria36. Hs-CRP was assessed using immunoassay and latex HS (IMMULITE 1000-High, 
Diagnostic Products Corporation, LA, CA, USA), with maximum intra- and interbatch coefficients 
of variation of 1.3% and 4.6%, respectively33. For cytokine and adipokine measurements, serum 
samples were stored at -80°C before assessment and sent on dry ice to the laboratory. Cytokine 
concentrations were measured using a multiplexed particle-based flow cytometric cytokine 
assay37. Lower detection limits (LOD) for interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor 
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necrosis factor-α (TNF-α) were 0.2 pg/ml. For concentrations below the LOD (37.5% for IL-1β, 
8.2% for IL-6, 0.7% for TNF-α) a value of 0.1 pg/ml was assigned. Good agreement between 
signal and cytokine was found within the assay range (R2≥0.99). Adiponectin was assessed by 
ELISA (R&D Systems, Inc, Minneapolis, USA) with a maximum inter- and intra-assay CV of 
8.3%. Leptin was assessed by ELISA (American Laboratory Products Company, Windham, 
USA) with a maximum inter- and intra-assay CV of 12.8% and 5.8%, respectively.  
 
Information on socio-demographic characteristics, current medication, alcohol consumption, 
smoking and physical activity was collected through a standardized interview. Caucasian origin 
was defined as having both parents and grandparents born in a restricted list of countries 
(available from the authors). Socio-economic status (SES) was determined using the 
Hollingshead scale38. Subjects were considered to be physically active if they reported physical 
activity for at least 20 minutes twice a week. Daily energy and carbohydrate consumption at 
follow-up were assessed using a validated, self-administered, quantitative Food Frequency 
Questionnaire39, 40.  
 
Diagnostic information on mental disorders was collected at baseline and follow-up using the 
French version of the semi-structured Diagnostic Interview for Genetic Studies (DIGS)41, 42. The 
DIGS was completed with anxiety disorder sections of the Schedule for Affective Disorders and 
Schizophrenia - Lifetime Version (SADS-L)43. Psychiatric lifetime diagnoses were assigned 
according to the DSM-IV44. Criteria for atypical features include mood reactivity and at least two 
of the following four symptoms: 1) increased appetite or significant weight gain, 2) hypersomnia, 
3) leaden paralysis, and 4) interpersonal rejection sensitivity. In order to avoid potential 
redundancy with the metabolic disorder component abdominal waist circumference, we only 
applied the appetite part of the appetite/weight gain criterion. The melancholic features specifier 
requires either a loss of energy or a lack of mood reactivity and three out of the following five 
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symptoms: 1) depression regularly worse in the morning, 2) early morning awakening, 3) 
psychomotor retardation or agitation, 4) decreased appetite (we did not consider weight loss as 
a criterion) and 5) excessive guilt. We could not take into account the criterion “distinct quality of 
depressed mood” because it was not assessed in the DIGS. MDD was subdivided according to 
the lifetime history of episodes with atypical or melancholic features into three subtypes: 1) MDD 
with atypical features only, 2) MDD with melancholic features only, 3) unspecified MDD with 
neither atypical nor melancholic features or with both atypical and melancholic features. The 
DIGS also assesses lifetime binge eating and early physical or sexual abuse. For subjects who 
refused the DIGS interview at follow-up (11.5%), MDD status at follow-up was assessed using 
the Centre for Epidemiologic Studies Depression (CES-D) scale. A score of 19 or higher was 
considered to be an indicator of the presence of a major depressive episode (MDE)45, 46. 
Interviewers were master-level psychologists, who were trained over a two-month period. Each 
interview and diagnostic assignment was reviewed by an experienced senior psychologist. 
 
The Institutional Ethics’ Committee of the University of Lausanne approved the 
CoLaus|PsyCoLaus study. All participants signed a written informed consent after having 
received a detailed description of the goal and funding of the study. 
 
Statistical	analysis	
Analyses were performed separately for Caucasians and Non-Caucasians using the Statistical 
Analysis System (SAS, Cary, NC, USA), version 9.3, for Windows. The associations between 
lifetime MDD subtype status and changes in cardio-metabolic outcomes during follow-up 
(difference between follow-up and baseline levels for waist circumference, fasting glucose, HDL-
cholesterol, triglycerides, systolic blood pressure (SBP)) were assessed using robust47 rather 
than multiple regression models, given that the residuals did not reveal a normal distribution. 
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Subjects with medication for a specific cardio-metabolic condition at baseline (antidiabetic drugs, 
fibrates, antihypertensive drugs) were excluded from the respective analyses (Figure 1). 
Analyses with the incidence of the metabolic syndrome as the outcome variable were performed 
using logistic regression. In order to adjust for the effects of medication prescribed during the 
follow-up, values for treated subjects were assigned according to documented mean changes 
under medication48. For subjects treated with antidiabetic medication (n=63) a value of 7.0 
mmol/l was assigned when the glucose level was less than 7.0 mmol/l; for those using fibrates 
(n=12) 0.10 mmol/l was subtracted from HDL-cholesterol and 0.67 mmol/l was added to 
triglycerides, and for those using antihypertensive drugs (n=251) 10 mmHg was added to the 
SBP. In order to test whether inflammatory marker or adipokine concentrations at baseline and 
the change in waist circumference during follow-up were likely to be mediators of the 
associations between lifetime MDD subtype status and changes in cardio-metabolic outcomes, 
we used serially adjusted models. Model 1 was adjusted for potential confounding variables 
including socio-demographic characteristics (sex, age, SES, living alone), current vs. remitted 
status, baseline level of the cardio-metabolic outcome variable, length of follow-up, occurrence 
of depressive episodes during follow-up, a lifetime history of comorbid anxiety disorders or drug 
dependence, health-related lifestyle factors (physical inactivity, alcohol consumption, smoking 
status), early physical or sexual abuse and treatment with antidepressants or possibly weight-
increasing drugs (list extracted from micromedex49 and the Swiss Compendium of 
Medications50). Model 2 was also adjusted for the effects of inflammatory markers and 
adipokines (only in Caucasians) and Model 3 also accounted for the change of waist 
circumference during follow-up. Inflammatory marker and adipokine concentrations were log-
transformed and standardized. In case of significant associations between the MDD subtypes 
and metabolic outcomes, additional analyses tested the influence on these associations of 
eating behaviors such as binge eating at baseline and follow-up as well as daily energy and 
carbohydrate consumption at follow-up. Moreover, we assessed the associations between 
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specific depression symptoms and the cardio-metabolic outcomes. 
 
RESULTS 
Baseline	characteristics	
Table 1 presents the characteristics of the Caucasian sample by depression status at baseline. 
A proportion of 6.4% of the participants met lifetime criteria for MDD with atypical features, 
13.1% for MDD with melancholic features, and 24.3% for unspecified MDD (among them 15.3% 
with both atypical and melancholic features). All socio-demographic characteristics except for 
SES, length of follow-up, most of the behavioral factors, a lifetime history of anxiety disorders, 
early physical or sexual abuse, current versus remitted depression status, occurrence of 
depressive episodes during follow-up, antidepressant and weight-gain inducing medication  and 
cardio-metabolic risk factors were unequally distributed across diagnostic groups.  
Regarding the distribution of potential mediating variables at baseline (Table 2), the IL-1β 
concentration was lower and the leptin concentration was higher in subjects with atypical MDD 
as compared to never depressed individuals. Moreover, subjects with MDD revealed binge 
eating more frequently at baseline and follow-up and those with melancholic MDD also had a 
higher daily carbohydrate consumption at follow-up than never depressed individuals. In 
addition, insulin resistance according to the HOMA-IR index was elevated in subjects with 
atypical MDD at baseline.  
Among the 243 Non-Caucasians (15% Asians, 27% Africans, 19% Arabs and 38% Latin 
Americans), the lifetime prevalence of MDD subtypes was almost identical to that of Caucasians 
(6.4% MDD with atypical features, 13.2% MDD with melancholic features and 28.9% unspecified 
MDD). 
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Waist	circumference	
Table 3 provides the changes of cardio-metabolic characteristics during the follow-up in function 
of the baseline depression status. The results of the robust regression model with adjustment for 
potential confounders (Model 1) revealed that subjects with a lifetime history of both atypical and 
melancholic MDD at baseline had a steeper increase of waist circumference during follow-up 
than never depressed subjects. The size of these associations only marginally diminished after 
additional adjustments for inflammation marker or adipokine concentrations at baseline (Model 
2), although the hs-CRP and leptin concentrations were positively and the adiponectin 
concentration was negatively associated with increase in waist circumference. Additional 
analyses showed that eating behaviors did not account for the associations between increase of 
waist circumference and atypical (β=2.28 after adjustment instead of 2.35) or melancholic MDD 
(β=1.27 after adjustment instead of 1.36), although binge eating at follow-up was significantly 
associated with this metabolic outcome (β=2.27, 95% C.I. 0.01-4.52, p=0.049). Nevertheless, 
among the specific depression symptoms only the atypical depression symptom increased 
appetite during depressive episodes was a significant predictor of increase of waist 
circumference during the follow-up (β=2.30, 95% C.I. 1.31-3.30, p<0.001). In order to test 
whether the association between atypical MDD and increase in waist circumference was 
explained by increased appetite alone we ran an additional model testing this association with 
adjustment for the effect of this symptom. Despite a decrease of the effect size this model still 
revealed a significant association between atypical depression and increase in waist 
circumference (β=1.41 instead of 2.35, 95% C.I. 0.07-2.75, p=0.039), therefore supporting the 
contribution of other symptoms to this association. Among Non-Caucasians there was no 
significant association between MDD subtypes and increase of waist circumference (β=1.62, 
95% C.I. -2.63-5.88 for atypical MDD, β=-1.55, 95% C.I. -5.38-2.28 for melancholic MDD, β=-
2.83, 95% C.I. -6.29-0.64 for unspecified MDD according to Model 2). 
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Fasting	glucose	
After the exclusion of subjects treated with antidiabetic drugs, those with atypical and 
melancholic MDD revealed a steeper increase of fasting glucose levels during follow-up than 
never depressed individuals (Model 1). Additional adjustments for baseline inflammation 
markers and adipokines (Model 2) as well as change of waist circumference during follow-up 
(Model 3) led to a moderate decrease of the β-estimate for atypical MDD, although baseline hs-
CRP and leptin concentrations were positively and IL-1β and adiponectin concentrations 
negatively associated with increase in fasting glucose levels. In contrast, the effect of 
melancholic MDD on glucose increase no longer reached the level of statistical significance after 
adjustment for increase of waist circumference. An additional analysis showed that, after adding 
the effect of the baseline HOMA-IR index to Model 1, this indicator of insulin resistance was 
associated with glucose level increase (β=40; 95% C.I. 18-61; p<0.001) at follow-up and also 
slightly decreased the estimate for atypical MDD (reduction of β for atypical MDD from 149 to 
145). In contrast, eating behaviors had no effect on the size of the association between atypical 
and melancholic MDD and glucose level increase (β=149 and 89 respectively after adjustment 
for eating behaviors). None of the five criteria for atypical depression features were significantly 
associated with this metabolic outcome.  
Regarding Non-Caucasians both atypical MDD (β=448, 95% C.I. 125-771, p=0.007 according to 
Model 3) and unspecified MDD (β=382, 95% C.I. 120-644, p=0.003 according to Model 3) were 
associated with glucose level increase regardless of the number of adjustments.  
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HDL‐cholesterol,	triglycerides	and	systolic	blood	pressure	
Regarding HDL-cholesterol, triglycerides and SBP, except for an association between 
unspecified MDD and decrease of SBP, depression status was not associated with changes of 
these cardio-metabolic outcomes during follow-up regardless of the number of adjustments. In 
contrast, higher concentrations of IL-6 at baseline predicted a decrease in triglyceride levels 
during follow-up. Similarly, higher baseline adiponectin concentrations were associated with a 
decrease in triglyceride levels during follow-up whereas leptin concentrations were associated 
with a decrease in HDL cholesterol and an increase in triglyceride levels. Among Non-
Caucasians, the melancholic subtype was associated with HDL-cholesterol increase during 
follow-up (β=188, 95% C.I. 15-361, p=0.033 according to Model 3).  
 
Metabolic	syndrome	
A total of 522 Caucasian subjects met diagnostic criteria for the metabolic syndrome at baseline 
and were excluded from analyses regarding the incidence of this syndrome. Among the 
remainders, 375 subjects (16.5%) developed the metabolic syndrome during the follow-up. 
Table 4 reveals that atypical MDD at baseline was significantly associated with the incidence of 
the metabolic syndrome after adjustment for potential confounders (Model 1) and after adding 
inflammation marker or adipokine levels (Model 2). In addition, increased IL-1β and adiponectin 
levels reduced the incidence of the metabolic syndrome. None of the five criteria for atypical 
depression features were significantly associated with the incidence of the metabolic syndrome. 
Among Non-Caucasians, none of the MDD subtypes were significantly associated with the 
metabolic syndrome. 
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DISCUSSION 
The present community study is the first to assess the prospective associations of MDD 
subtypes with changes of specific cardio-metabolic characteristics and the incidence of the 
metabolic syndrome and the influence of inflammation marker and adipokine levels as well as 
eating behaviors on these associations. The main findings were that 1) the atypical MDD 
subtype, and only this subtype, is a predictor for a steeper increase and higher fasting glucose 
level as well as the incidence of the metabolic syndrome across a 5.5-year follow-up period; 2) 
the steeper increase of glucose levels in subjects with atypical MDD is not attributable to the 
increase of waist circumference, eating behaviors, inflammatory marker or adipokine 
concentrations but it is likely to be partially mediated by insulin resistance.  
 
The finding that only atypical MDD was prospectively associated with metabolic characteristics 
confirms results from previous cross-sectional research21, 22, 24 and further advocates for the 
subtyping of the heterogeneous depression diagnosis. This association pattern was similar for 
Caucasian and Non-Caucasian participants. Moreover, together with the recent findings of a 
Dutch cohort study over 6 years26, our results demonstrate that the association between atypical 
depression and metabolic outcomes is not simply attributable to the occurrence of atypical 
depressive symptoms in subjects already exhibiting metabolic diseases, but to a strong 
prospective association between the atypical MDD subtype and metabolic outcomes. 
Interestingly, the Dutch and our study converge in observing persistently higher BMI or waist 
circumference and a higher prevalence of the metabolic syndrome in patients with atypical 
depression as compared to unaffected subjects even after more than half of the group no longer 
had MDD in the Dutch study and after adjustment for the effect of the occurrence of new 
depressive episodes during follow-up in our study. Also the observed association between 
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unspecified MDD and decrease of SBP is compatible with cross-sectional findings of this Dutch 
study22. 
The present study provides additional insight into the complex relationship between atypical 
depression and metabolic outcomes by suggesting the existence of two independent pathways. 
First, atypical MDD and the atypical depression symptom increased appetite were associated 
with a steeper increase of waist circumference, which persisted after remission of the depressive 
episode25. Second, the present results suggest that, independently of an increase in appetite or 
obesity, atypical depression is also associated with glucose level increase, which is likely to 
ultimately lead to diabetes. Regarding mechanisms that could link atypical depression and 
metabolic outcomes, it is possible that the increase of appetite related to the depressed episode 
temporarily persisted during the follow-up period and thereby contributed to the increase of waist 
circumference even after the offset of the depressive episode, although the increase of waist 
circumference in these subjects was not attributable to particularities in eating behaviors as 
assessed at the follow-up evaluation. However, although among the atypical depression 
symptoms only increased appetite significantly predicted increase of waist circumference, our 
data suggest that other symptoms also contribute to this metabolic outcome given that the 
association between atypical MDD and increase of waist circumference remained significant 
after adjustment for the effect of increased appetite. In contrast to increase of waist 
circumference, the symptom increased appetite was not associated with increase of glucose 
level during the follow-up or any other metabolic outcome. Our data also revealed that lifestyle 
factors including physical inactivity, smoking, or alcohol consumption, early physical or sexual 
abuse, comorbid psychiatric conditions, antidepressants or other potentially weight-increasing 
medication hardly explain the associations between atypical MDD and waist circumference or 
glucose level increase. The same was true for baseline adipokines and inflammatory markers, 
although adipokines were predictive for changes in most metabolic outcomes and the hs-CRP 
was a significant predictor of glucose level increase. In contrast insulin resistance, which was 
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significantly associated with both atypical MDD at baseline and glucose level increase during the 
follow-up, is likely to be a modest mediator of the association between atypical MDD at baseline 
and subsequent glucose level increase, whereas eating behaviors were not mediators of this 
association in our data. The independence of glucose level increase from eating behaviors was 
further evidenced by the fact that this metabolic outcome was not associated with the atypical 
depression symptom increased appetite. Other mechanisms that could underlie the association 
between atypical MDD and metabolic outcomes are the functioning of the HPA axis, which 
however was not found to be altered in subjects with atypical depression in a previous study22, 
and shared genes. Regarding obesity, the FTO gene, which could be related to atypical 
depression51 has been shown to selectively favor weight gain in depressed subjects52. Other 
genes may link atypical depression and glucose level changes despite previous negative 
evidence from twin and GWAS studies, which however relied on overall depression diagnoses53, 
54. 
 
Our findings should be considered in the context of several limitations. First, 459 participants 
(13%) who did not participate at the follow-up visit had to be excluded from our analyses. 
However, although non-participation was associated with a less healthy lifestyle, differential bias 
is unlikely as non-participation did not differ across diagnostic groups. Second, the Non-
Caucasian sample was relatively small and information on baseline adipokine levels was 
missing. Third, data were based on an urban sample in Switzerland, which may partially explain 
the high prevalence of MDD. However, it is unlikely that the specific characteristics of this 
sample significantly affected the assessed prospective associations between MDD subtypes, 
inflammation marker or adipokine levels and metabolic characteristics. Fourth, our assessment 
of physical activity only partially reflected daily activity and energy expenditure. Fifth, we could 
not test the effects of cortisol because this variable was not assessed at baseline. Sixth, data on 
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carbohydrate and caloric consumption were only available for the follow-up but not the baseline 
evaluation. 
In conclusion, our results support differential biological profiles of MDD subtypes in both 
Caucasians and Non-Caucasians by demonstrating a strong, prospective association restricted 
to the atypical subtype and glucose level increase, which in conjunction with the independent 
increase of waist circumference, may ultimately expose these subjects to elevated 
cardiovascular vulnerability and other diseases associated with metabolic dysregulations. This 
vulnerability is likely to be particularly high among subjects with atypical MDD and elevated 
levels of inflammation. Accordingly, the prevention and treatment of metabolic consequences in 
patients with atypical MDD deserve particular clinical attention. Further research including 
genotypic and HPA-axis data needs to determine to which degree these variables account for 
the steeper waist circumference and glucose increase among subjects with atypical MDD. In 
contrast, metabolic mechanisms hardly explain the potentially elevated cardiovascular risk 
among subjects with other subtypes of MDD. Hence, other biological pathways such as the 
HPA-axis need to be studied in these subjects. 
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FIGURE LEGENDS 
Figure 1: Flow chart of the study for the association between depressive subtypes at baseline 
and cardio-metabolic risk factors at follow-up. 
Key: MDD: Major depressive disorder 
 
      = Baseline assessment 
      =  Follow-up assessment 
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Table 1: Characteristics of participants (among Caucasians, n=2813) 
  Major Depressive Disorder (MDD) status at baseline 
Atypical Melancholic Unspecified No MDD   
  (n=179) (n=369) (n=685) (n=1580) χ2/F p-value 
Socio-demographic characteristics           
Age, mean (SD), y 49.1 (8.9) 49.5 (8.7) 49.4 (8.8) 50.5 (8.9) F3=3.7 0.011 
Men, % 27.9 31.7 37.2 57.0 χ32=150.0 <0.001 
Socio-economic status1, mean (SD) 3.4 (1.1) 3.5 (1.2) 3.5 (1.2) 3.4 (1.2) F3=1.6 n.s. 
Living alone, % 29.6 29.3 29.2 19.8 χ32=34.2 <0.001 
Length of follow-up, mean (SD), y 5.5 (0.3) 5.5 (0.3) 5.5 (0.4) 5.6 (0.4) F3=4.3 0.005 
Behavioral factors             
Physically inactive2, % 43.6 39.0 41.8 40.9 χ32=1.3 n.s. 
Smoking status, %           
   Current 27.9 29.5 32.9 24.9 χ32=15.7 0.001 
   Former 30.2 30.4 33.3 33.5 χ32=2.0 n.s. 
Number of alcoholic drinks per week, mean (SD) 4.9 (5.3) 5.7 (7.8) 6.2 (7.9) 8.0 (10.0) F3=13.3 <0.001 
Comorbid disorders             
Substance dependence3, % 0.6 3.0 3.2 2.2 χ32=5.5 n.s. 
Anxiety disorders4, % 25.7 27.9 23.4 12.4 χ32=78.6 <0.001 
Early trauma             
Early physical or sexual abuse, % 5.0 2.7 1.6 0.6 χ32=28.1 <0.001 
Depression status at baseline and follow-up             
Current major depressive episode, % 24.6 17.1 14.3 n/a χ32=10.9 0.004 
Major depressive episode during follow-up, % 13.0 15.6 13.9 6.2 χ32=51.3 <0.001 
Medication at baseline             
Antidiabetic drugs, % 2.2 1.9 3.5 2.7 χ32=2.6 n.s. 
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Fibrates, % 0.6 0.3 0.2 0.8 χ32=4.5 n.s. 
Nicotinic acid, % 0.0 0.0 0.0 0.0 n/a n/a 
Antihypertensive drugs, % 19.0 14.9 15.8 15.5 χ32=1.7 n.s. 
Antidepressant use, % 21.2 20.3 12.1 2.6 χ32=187.5 <0.001 
Weight-gain-inducing drug use, % 25.1 22.2 21.0 10.6 χ32=69.5 <0.001 
Cardio-metabolic risk factors at baseline 
Waist (cm), mean (SD) 88.7 (13.7) 85.3 (13.9) 85.9 (12.6) 89.0 (12.9) F3=14.4 <0.001 
Fasting glucose5, mean (SD), mmol/l 5.3 (0.7) 5.4 (1.0) 5.4 (1.1) 5.5 (1.0) F3=6.1 <0.001 
HDL cholesterol5, mean (SD), mmol/l 1.7 (0.5) 1.7 (0.4) 1.7 (0.4) 1.6 (0.4) F3=5.4 0.001 
Triglycerides5, mean (SD), mmol/l 1.4 (1.1) 1.3 (0.9) 1.3 (1.0) 1.4 (1.1) F3=1.7 n.s. 
Systolic blood pressure5, mean (SD), mmHg 126.2 (18.3) 124.2 (16.3) 124.0 (16.8) 128.2 (17.9) F3=12.0 <0.001 
Metabolic syndrome6, % 22.4 17.1 15.9 19.5 χ32=6.4 n.s. 
 
Key: SD: standard deviation, HDL: high-density lipoprotein cholesterol, n.s.: not significant. 
Χ2/F: Comparison with subjects with no MDD based on chi-square tests (categorical variables) /ANOVA (continuous variables). 
 
1 A value of 3 represents an SES of III (middle class) on the Hollingshead Scale. 
2 Physically inactive less than 20 minutes twice a week. 
3 Lifetime dependence on cocaine, stimulant, sedative, or hallucinogen. 
4 Generalized anxiety disorder, social phobia, panic disorder, or agoraphobia. 
5Prefixed values according to medication added (see methods section). 
6Metabolic syndrome according to adjusted Adult Treatment Panel III criteria (see methods section). 
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Table 2: Potential mediators by depression status at baseline among Caucasians (n=2813) 
  Major Depressive Disorder (MDD) at baseline 
Atypical Melancholic Unspecified No MDD 
Median Test statistics1 Median Test statistics1 Median Test statistics1 Median 
(IQR) (95%CI) (IQR) (95%CI) (IQR) (95%CI) (IQR) 
Inflammatory markers and adipokine 
concentrations at baseline               
Interleukin-1β, pg/ml 0.31 OR2=0.72* 0.43 OR2=0.91 0.42 OR2=0.91 0.43 
(0.10,1.66) (0.52,0.99) (0.10,1.98) (0.72,1.15) (0.10,2.00) (0.76,1.10) (0.10,1.94) 
Interleukin-6 , pg/ml 1.29 β=0.05 1.22 β=-0.08 1.19 β=-0.10 1.35 
(0.56,3.47) (-0.20,0.30) (0.52,2.81) (-0.26,0.11) (0.50,3.21) (-0.25,0.05) (0.60,3.39) 
Tumour necrosis factor-α, pg/ml 2.96 β=0.09 2.72 β=-0.02 2.61 β=-0.06 2.87 
(1.84,4.93) (-0.06,0.23) (1.62,4.29) (-0.13,0.08) (1.58,4.18) (-0.15,0.02) (1.86,4.45) 
hs-CRP, mg/l  1.20 β=0.15 1.00 β=-0.05 1.00 β=-0.07 1.10 
(0.60,2.60) (-0.02,0.31) (0.50,2.30) (-0.17,0.07) (0.50,2.10) (-0.16,0.03) (0.50,2.30) 
Adiponectin, μg/ml 9.36 β=-0.03 9.33 β=-0.01 8.79 β=0.02 7.82 
(5.69,12.98) (-0.12,0.07) (5.42,13.75) (-0.08,0.06) (5.61,13.72) (-0.04,0.07) (4.97,11.84) 
Leptin, ng/ml 11.78 β=0.16* 10.86 0.06 9.97 β=0.01 8.30 
(6.61,21.44) (0.04,0.28) (6.03,18.22) (-0.04,0.15) (5.18,18.39) (-0.06,0.09) (4.66,15.16) 
Eating behaviors %   %   %   % 
Binge eating at baseline 5.6 OR=3.3** 3.3 OR=2.0 3.8 OR=2.5** 1.1 
  (1.5,7.3)   (0.9,4.2)   (1.3,4.6)   
Binge eating at follow-up 3.4 OR=8.9*** 2.4 OR=6.6*** 1.6 OR=4.4** 0.3 
  (2.6,30.4)   (2.2,20.3)   (1.5,12.8)   
  Mean   Mean   Mean   Mean 
(SD) (SD) (SD) (SD) 
Energy consumption at follow-up, kcal/day 1708.7 β=-40.6 1799.0 β=64.7 1817.3 β=15.0 1869.9 
(686.8) (-140.4,59.3) (657.7) (-8.6,138.0) (727.7) (-43.2,73.2) (730.6) 
Carbohydrate consumption at follow-up,  kcal/day 784.7 β=-18.8 855.1 β=48.4* 848.1 β=16.1 851.8 
  (361.7) (-73.9,36.3) (363.2) (7.9,88.6) (401.0) (-16.1,48.2) (370.8) 
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Insulin resistance at baseline Median   Median   Median   Median 
(IQR) (IQR) (IQR) (IQR) 
Homeostatic model assessment - insulin 
resistance (HOMA-IR) 1.75 β=0.13* 1.56 β=0.05 1.50 β=0.00 1.57 
  (1.06,2.62) (0.03,0.23) (1.07,2.40) (-0.03,0.12) (1.01,2.24) (-0.06,0.06) (1.08,2.45) 
 
Key: hs-CRP: high-sensitivity C-reactive protein,IQR: interquartile range, 95%CI: 95% confidence interval, OR: odd ratio, SD: standard deviation. 
 
1 Adjusted for age, sex, socio-economic status and living alone. 
2 Logistic regression with Interleukin-1 beta concentration dichotomized at the median due to many (37.5%) values below the LOD. 
* p<0.05, ** p<0.01, *** p<0.001 
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Table 3: Cardio-metabolic characteristics at baseline and change during follow-up by depression status at baseline among 
Caucasians 
  Change during follow-up 
Crude change Model 1 Model 2 Model 3 
Mean (SD) β1 (95%CI) β (95%CI) β (95%CI) β (95%CI) 
Waist circumference, cm (n=2796)                   
Depression status            
      Atypical 4.6 (7.9) 1.58** (0.60,2.56) 2.35*** (1.11,3.58) 2.41*** (1.19,3.63) - - 
      Melancholic 4.7 (8.0) 0.64 (-0.08,1.35) 1.36* (0.28,2.45) 1.43** (0.36,2.51) - - 
      Unspecified 3.7 (7.1) 0.04 (-0.53,0.61) 0.65 (-0.35,1.65) 0.76 (-0.23,1.75) - - 
      No major depressive disorder (ref.) 3.2 (6.3)         
Interleukin-1β (cont.) - 0.03 (-0.21,0.26) - - -0.09 (-0.37,0.18) - - 
Interleukin-6 (cont.) - 0.11 (-0.12,0.34) - - 0.08 (-0.18,0.35) - - 
Tumour necrosis factor-α (cont.) - 0.10 (-0.13,0.34) - - -0.02 (-0.28,0.24) - - 
hs-CRP (cont.) - 0.63*** (0.37,0.90) - - 0.44** (0.18,0.71) - - 
Adiponectin (cont.) - -0.38** (-0.64,-0.12) - - -0.33* (-0.59,-0.07) - - 
Leptin (cont.) - 1.09*** (0.77,1.42) - - 1.07*** (0.74,1.39) - - 
Fasting glucose, μmol/l (n=2721)           
Depression status            
      Atypical 502 (685) 106** (32,180) 149** (55,244) 143** (49,237) 131** (38,225) 
      Melancholic 329 (775) 35 (-20,89) 90* (6,174) 95* (12,179) 79 (-4,162) 
      Unspecified 394 (630) 13 (-31,56) 64 (-13,141) 76 (-1,153) 70 (-6,147) 
      No major depressive disorder (ref.) 383 (747)         
Interleukin-1β (cont.) - -14 (-32,4) - - -24* (-45,-3) -24* (-45,-3) 
Interleukin-6 (cont.) - 16 (-2,34) - - 19 (-1,40) 20 (-1,40) 
Tumour necrosis factor-α (cont.) - 4 (-13,22) - - 0 (-20,20) 0 (-20,20) 
hs-CRP (cont.) - 58*** (40,76) - - 41*** (21,61) 40*** (20,60) 
Adiponectin (cont.) - -36*** (-56,-16) - - -29** (-49,-9) -29** (-49,-10) 
Leptin (cont.) - 46*** (25,67) - - 27* (4,49) 26* (4,48) 
Change of waist circumference (cont.) - 56*** (38,74) - - - - 53*** (35,71) 
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HDL cholesterol, μmol/l (n=2783)                   
Depression status            
      Atypical -29 (253) -33 (-70,5) -38 (-86,9) -36 (-83,11) -27 (-74,19) 
      Melancholic -8 (285) -18 (-46,9) -34 (-76,8) -34 (-76,7) -26 (-68,15) 
      Unspecified 0 (277) -14 (-36,8) -28 (-67,10) -30 (-68,9) -24 (-62,14) 
      No major depressive disorder (ref.) 3 (274)         
Interleukin-1β (cont.) - 3 (-6,12) - - 1 (-10,11) 0 (-11,11) 
Interleukin-6 (cont.) - -2 (-11,8) - - -2 (-13,8) -1 (-11,9) 
Tumour necrosis factor-α (cont.) - 2 (-7,11) - - 4 (-6,14) 4 (-6,14) 
hs-CRP (cont.) - -11* (-20,-2) - - -4 (-14,6) -4 (-14,6) 
Adiponectin (cont.) - 0 (-10,11) - - 0 (-11,10) -1 (-11,9) 
Leptin (cont.) - -27*** (-38,-17) - - -24*** (-35,-13) -24*** (-35,-13) 
Change of waist circumference (cont.) - -38*** (-47,-29) - - - - -39*** (-48,-30) 
Triglycerides, μmol/l (n=2783)                   
Depression status            
      Atypical 54 (1012) 13 (-52,79) -14 (-97,70) -11 (-94,73) -23 (-106,59) 
      Melancholic -16 (735) 16 (-32,64) -15 (-89,58) -14 (-88,59) -27 (-99,46) 
      Unspecified 40 (888) 17 (-21,55) -15 (-84,53) -11 (-79,57) -12 (-79,55) 
      No major depressive disorder (ref.) 16 (940)         
Interleukin-1β (cont.) - 2 (-14,18) - - 9 (-10,28) 9 (-10,28) 
Interleukin-6 (cont.) - -12 (-27,4) - - -20* (-38,-2) -21* (-39,-3) 
Tumour necrosis factor-α (cont.) - 3 (-13,18) - - -1 (-18,17) -1 (-19,17) 
hs-CRP (cont.) - 23** (7,40) - - 12 (-6,30) 11 (-6,28) 
Adiponectin (cont.) - -54*** (-71,-36) - - -49*** (-67,-32) -48*** (-65,-30) 
Leptin (cont.) - 35*** (17,54) - - 28** (8,47) 26* (6,45) 
Change of waist circumference (cont.) - 76*** (60,92) - - - - 75*** (59,91) 
Systolic blood pressure, mmHg (n=2364)                   
Depression status            
      Atypical -1.2 (15.2) -1.05 (-3.01,0.90) -1.75 (-4.23,0.73) -1.80 (-4.28,0.69) -2.00 (-4.48,0.48) 
      Melancholic 0.2 (11.6) -0.60 (-2.01,0.81) -1.31 (-3.46,0.84) -1.32 (-3.47,0.83) -1.46 (-3.60,0.69) 
      Unspecified -0.3 (12.7) -1.53** (-2.65,-0.41) -2.34* (-4.31,-0.37) -2.29* (-4.26,-0.31) -2.22* (-4.19,-0.26) 
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      No major depressive disorder (ref.) 1.0 (12.4)         
Interleukin-1β (cont.) - -0.23 (-0.68,0.23) - - -0.35 (-0.91,0.21) -0.35 (-0.90,0.21) 
Interleukin-6 (cont.) - -0.13 (-0.58,0.33) - - -0.05 (-0.59,0.49) -0.04 (-0.58,0.50) 
Tumour necrosis factor-α (cont.) - -0.01 (-0.47,0.44) - - 0.09 (-0.43,0.61) 0.09 (-0.43,0.60) 
hs-CRP (cont.) - 0.27 (-0.20,0.74) - - 0.18 (-0.33,0.68) 0.15 (-0.36,0.65) 
Adiponectin (cont.) - -0.45 (-0.95,0.06) - - -0.38 (-0.89,0.13) -0.37 (-0.88,0.14) 
Leptin (cont.) - 0.27 (-0.28,0.81) - - 0.12 (-0.46,0.70) 0.10 (-0.48,0.68) 
Change of waist circumference (cont.) - 1.15*** (0.68,1.61) - - - - 1.17*** (0.71,1.64) 
 
Key: hs-CRP: high-sensitivity C-reactive protein, HDL: high-density lipoprotein cholesterol, SD: standard deviation, 95%CI: 95% confidence interval, 
ref.: reference group, cont.: continuous variable. 
1Bivariate associations adjusted for age, sex and cardio-metabolic risk factors at baseline. 
 
Model 1 adjusted for socio-demographic characteristics, length of follow-up, behavioral factors, comorbid disorders, early trauma, depression status 
at baseline and follow-up, medication at baseline and cardio-metabolic risk factors at baseline. 
Model 2 = Model 1 additionally adjusted for inflammatory marker and adipokine concentrations at baseline. 
Model 3 = Model 2 additionally adjusted for change of waist circumference. 
* p<0.05, ** p<0.01, *** p<0.001. 
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Table 4: Incidence of the metabolic syndrome at follow-up by depression status at 
baseline (among Caucasians, N=2274) 
  Incidence of the Metabolic Syndrome 
Crude Model 1 Model 2 
Characteristics at baseline % OR1 95%CI OR 95%CI OR 95%CI 
Depression status                
      Atypical 25.6 2.38*** (1.55,3.65) 2.56** (1.35,4.87) 2.49** (1.30,4.77)
      Melancholic 13.1 0.94 (0.65,1.37) 1.49 (0.81,2.75) 1.45 (0.78,2.69)
      Unspecified 15.1 1.06 (0.80,1.40) 1.44 (0.84,2.47) 1.44 (0.83,2.49)
      No major depressive disorder (ref.) 16.9 1 (ref.)       
Interleukin-1β (cont.) - 0.92 (0.81,1.03) - - 0.84* (0.72,0.99)
Interleukin-6 (cont.) - 1.07 (0.96,1.20) - - 1.04 (0.89,1.22)
Tumour necrosis factor-α (cont.) - 1.10 (0.99,1.24) - - 1.02 (0.87,1.19)
hs-CRP (cont.) - 1.63*** (1.44,1.84) - - 1.06 (0.91,1.23)
Adiponectin (cont.) - 0.65*** (0.57,0.74) - - 0.82* (0.70,0.95)
Leptin (cont.) - 1.98*** (1.71,2.29) - - 1.19 (0.99,1.44)
 
Key: hs-CRP: high-sensitivity C-reactive protein, OR: odd ratio, 95%CI: 95% confidence interval, ref.: 
reference group, cont.: continuous variable. 
1Bivariate associations adjusted for age and sex. 
Model 1 adjusted for socio-demographic characteristics, length of follow-up, behavioral factors, comorbid 
disorders, early trauma, depression status at baseline and follow-up, medication at baseline and cardio-
metabolic risk factors at baseline. 
Model 2 = Model 1 additionally adjusted for inflammatory marker and adipokine concentrations at 
baseline. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
